Bionovis’s Acquisition of technologies to Produce Trastuzumab

Cescon, Barrieu, Flesch & Barreto and Demarest advised on the deal

Bionovis executed the acquisition ot the technology to produce Trastuzumab from Samsung Bioepis.

Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer.

Bionovis engages in pharmaceutical industry. The company was founded in 2010 in the city of Rio de Janeiro.

Cescon, Barrieu, Flesch & Barreto advised Bionovis S.A. with Ana Carolina Castro Reis Passos (Picture).

Demarest advised Samsung Bioepis with Bruno de Luca Drago, Milena Fernandes Mundim and Mariana Llamazalez Ou.

Involved fees earner: Ana Carolina Castro Reis Passos – Cescon, Barrieu, Flesch & Barreto; Bruno de Luca Drago – Demarest; Milena Fernandes Mundim – Demarest; Mariana LLamazalez – Demarest;

Law Firms: Cescon, Barrieu, Flesch & Barreto; Demarest;

Clients: Bionovis SA; Samsung Bioepis Co Ltd;

Author: Ambrogio Visconti.